FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361827502> ?p ?o ?g. }

• W4361827502 abstract "<div>Abstract<p><b>Purpose:</b> To determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322 (BMS-844203), a VEGFR-2 inhibitor and the first human fibronectin domain–based targeted biologic (Adnectin) to enter clinical studies.</p><p><b>Experimental Design:</b> Patients with advanced solid malignancies were treated with escalating doses of CT-322 intravenously (i.v.) weekly (qw), or biweekly (q2w). Plasma samples were assayed for CT-322 concentrations, plasma VEGF-A concentrations, and antidrug antibodies.</p><p><b>Results:</b> Thirty-nine patients completed 105 cycles of 0.1 to 3.0 mg/kg CT-322 i.v. either qw or q2w. The most common treatment-emergent grade 1/2 toxicities were fatigue, nausea, proteinuria, vomiting, anorexia, and hypertension. Grade 3/4 toxicities were rare. Reversible proteinuria, retinal artery, and vein thrombosis, left ventricular dysfunction, and reversible posterior leukoencephalopathy syndrome were dose limiting at 3.0 mg/kg. The MTD was 2 mg/kg qw or q2w. CT-322 plasma concentrations increased dose proportionally. Plasma VEGF-A levels increased with dose and plateaued at 2 mg/kg qw. Anti–CT-322 antibodies developed without effects on pharmacokinetics, VEGF-A levels, or safety. Minor decreases in tumor measurements occurred in 4 of 34 evaluable patients and 24 patients had stable disease.</p><p><b>Conclusions:</b> CT-322 can be safely administered at 2 mg/kg i.v. qw or q2w and exhibits promising antitumor activity in patients with advanced solid tumors. The absence of severe toxicities at the MTD, demonstration of plasma drug concentrations active in preclinical models, and clinical pharmacodynamic evidence of VEGFR-2 inhibition warrant further development of CT-322 and suggest strong potential for Adnectin-based targeted biologics. <i>Cancer Res; 17(2); 363–71. ©2011 AACR</i>. <i>Clin Cancer Res; 17(2); 363–71. ©2011 AACR</i>.</p></div>" @default.
• W4361827502 created "2023-04-05" @default.
• W4361827502 creator A5000961519 @default.
• W4361827502 creator A5002909668 @default.
• W4361827502 creator A5008969784 @default.
• W4361827502 creator A5015929627 @default.
• W4361827502 creator A5024771370 @default.
• W4361827502 creator A5026484266 @default.
• W4361827502 creator A5028833538 @default.
• W4361827502 creator A5033022984 @default.
• W4361827502 creator A5044878283 @default.
• W4361827502 creator A5059997105 @default.
• W4361827502 creator A5060992997 @default.
• W4361827502 creator A5068880893 @default.
• W4361827502 creator A5070570779 @default.
• W4361827502 date "2023-03-31" @default.
• W4361827502 modified "2023-09-27" @default.
• W4361827502 title "Data from Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin" @default.
• W4361827502 doi "https://doi.org/10.1158/1078-0432.c.6519701.v1" @default.
• W4361827502 hasPublicationYear "2023" @default.
• W4361827502 type Work @default.
• W4361827502 citedByCount "0" @default.
• W4361827502 crossrefType "posted-content" @default.
• W4361827502 hasAuthorship W4361827502A5000961519 @default.
• W4361827502 hasAuthorship W4361827502A5002909668 @default.
• W4361827502 hasAuthorship W4361827502A5008969784 @default.
• W4361827502 hasAuthorship W4361827502A5015929627 @default.
• W4361827502 hasAuthorship W4361827502A5024771370 @default.
• W4361827502 hasAuthorship W4361827502A5026484266 @default.
• W4361827502 hasAuthorship W4361827502A5028833538 @default.
• W4361827502 hasAuthorship W4361827502A5033022984 @default.
• W4361827502 hasAuthorship W4361827502A5044878283 @default.
• W4361827502 hasAuthorship W4361827502A5059997105 @default.
• W4361827502 hasAuthorship W4361827502A5060992997 @default.
• W4361827502 hasAuthorship W4361827502A5068880893 @default.
• W4361827502 hasAuthorship W4361827502A5070570779 @default.
• W4361827502 hasConcept C111113717 @default.
• W4361827502 hasConcept C112705442 @default.
• W4361827502 hasConcept C126322002 @default.
• W4361827502 hasConcept C197934379 @default.
• W4361827502 hasConcept C2780580376 @default.
• W4361827502 hasConcept C2780852908 @default.
• W4361827502 hasConcept C71924100 @default.
• W4361827502 hasConcept C90924648 @default.
• W4361827502 hasConcept C98274493 @default.
• W4361827502 hasConceptScore W4361827502C111113717 @default.
• W4361827502 hasConceptScore W4361827502C112705442 @default.
• W4361827502 hasConceptScore W4361827502C126322002 @default.
• W4361827502 hasConceptScore W4361827502C197934379 @default.
• W4361827502 hasConceptScore W4361827502C2780580376 @default.
• W4361827502 hasConceptScore W4361827502C2780852908 @default.
• W4361827502 hasConceptScore W4361827502C71924100 @default.
• W4361827502 hasConceptScore W4361827502C90924648 @default.
• W4361827502 hasConceptScore W4361827502C98274493 @default.
• W4361827502 hasLocation W43618275021 @default.
• W4361827502 hasOpenAccess W4361827502 @default.
• W4361827502 hasPrimaryLocation W43618275021 @default.
• W4361827502 hasRelatedWork W1980872763 @default.
• W4361827502 hasRelatedWork W2030972871 @default.
• W4361827502 hasRelatedWork W2041128529 @default.
• W4361827502 hasRelatedWork W2074629895 @default.
• W4361827502 hasRelatedWork W2164530441 @default.
• W4361827502 hasRelatedWork W2227061539 @default.
• W4361827502 hasRelatedWork W2358248846 @default.
• W4361827502 hasRelatedWork W243857094 @default.
• W4361827502 hasRelatedWork W2893772422 @default.
• W4361827502 hasRelatedWork W2992709639 @default.
• W4361827502 isParatext "false" @default.
• W4361827502 isRetracted "false" @default.
• W4361827502 workType "article" @default.